549534-58-9 Usage
Uses
Used in Peptide Synthesis:
(2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid is used as a building block in peptide synthesis for the incorporation of specific amino acid sequences into peptides. Its unique structure allows for the controlled formation of peptide bonds, facilitating the synthesis of complex peptide molecules with desired properties.
Used in Organic Chemistry:
In the field of organic chemistry, (2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid is used as a reagent or intermediate in various chemical reactions. Its protected amine and carboxylic acid functionalities enable selective reactions and transformations, making it a versatile component in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
(2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid is used as a key component in the development of pharmaceutical compounds. Its unique structure and functional groups can be utilized to create novel drug candidates with potential therapeutic applications.
Used in Research and Development:
In academic and industrial research settings, (2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid is used as a research tool to study the properties and reactivity of amino acids and their derivatives. Its stereochemistry and protecting groups provide insights into the behavior of chiral molecules and the influence of protecting groups on chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 549534-58-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,9,5,3 and 4 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 549534-58:
(8*5)+(7*4)+(6*9)+(5*5)+(4*3)+(3*4)+(2*5)+(1*8)=189
189 % 10 = 9
So 549534-58-9 is a valid CAS Registry Number.
549534-58-9Relevant academic research and scientific papers
Structure - Activity relationship studies of targeting ligands against breast cancer cells
Yao, Nianhuan,Xiao, Wenwu,Meza, Leah,Tseng, Harry,Chuck, Mathida,Lam, Kit S.
supporting information; experimental part, p. 6744 - 6751 (2010/04/04)
A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant. 2009 American Chemical Society.
